Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1985)
  2. Solid Tumor Oncology Division (1617)
  3. GSK Faculty (763)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2094)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (89)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1985)
  2. Solid Tumor Oncology Division (1617)
  3. GSK Faculty (763)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (82)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1668)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4629)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Deep learning-based classifier for carcinoma of unknown primary using methylation quantitative trait loci
    Journal Article

    Walker, A.; Fang, C. S.; Schroff, C.; Serrano, J.; Vasudevaraja, V.; Yang, Y.; Belakhoua, S.; Faustin, A.; William, C. M.; Zagzag, D.; more...
    Journal of Neuropathology and Experimental Neurology (2025)

    Fulltext@MSK | Save
  • Reply to the letter to the editor ‘circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima
    Correspondence

    Bercz, A.; Smith, J. J.; Romesser, P. B.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Early truncating mutations in ASXL1 drive reduced H3K27me3 across various central nervous system tumors
    Meeting Abstract

    Zhang, K.; Parker, M.; Weber-Levine, C.; Kalluri, A.; Gonzales-Gomez, I.; Raabe, E.; Dudley, J.; Gocke, C.; Lin, M.; Zou, Y.; more...
    Journal of Neuropathology and Experimental Neurology (2024)

    Fulltext@MSK | Save
  • Clinical and molecular landscape of TERT promoter mutant meningiomas
    Meeting Abstract

    Groff, K.; Patel, R.; Suwala, A.; Kresbach, C.; Youngblood, M.; Chen, W.; Cai, C.; Patel, A.; Bale, T.; Magill, S.; more...
    Journal of Neuropathology and Experimental Neurology (2024)

    Fulltext@MSK | Save
  • A new entity in glial tumors: CD34-expressing glioma with MEN1 alteration
    Meeting Abstract

    Yokoda, R. T.; Rosenblum, M.; Bale, T.; Vij, M.; Crary, J.; Walker, J.; Tsankova, N.; Bederson, J.; Richardson, T.; Umphlett, M.
    Journal of Neuropathology and Experimental Neurology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
    Meeting Abstract

    Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save